With a mission to improve people's health and longevity, Exeliom is at the forefront of developing innovative microbial therapies. Their Live Biotherapeutics, a new class of medicines, leverage the therapeutic potential of gut microbiota to treat immune-mediated diseases. Founded in 2016 and headquartered in Dijon, France, Exeliom Biosciences focuses on inflammatory bowel diseases, particularly Crohn's Disease, as its initial target for treatment. By developing single bacterial strain drug candidates, Exeliom aims to deliver groundbreaking microbiome-based therapeutics that can transform the field of medicine.